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Abstract 
Aim: The aim of this large randomized controlled study was to test the value of Aromatherapy (AM) with breast cancer patients for 
reducing symptoms, such as pain, anxiety, depression, emotional responses, insomnia, nausea/vomiting and the ability to cope.
Methods: 284 breast cancer patients, were randomized to receive AM provided by a charity-run cancer support centre for an hour 
a week for six weeks, or to receive care as usual.  Both groups completed the European Organization for Research and Treatment 
of Cancer quality of life questionnaire (EORTC QLQ-C30), EORTC breast (BR23) and the Hospital Anxiety and Depression Scale 
(HADS) questionnaires before at the first week, and after the third and sixth weeks.
Results: There was no significant difference in pain score between groups (p=0.409) or change in pain from baseline. There were 
however, improvements in the AM group in emotional functioning, fatigue and depression at six weeks (p<0.05 and medium effect 
sizes in all these outcomes).  Physical functioning, role functioning, breast symptoms e.g. pain, swelling, sensitivity, together with 
side effects and future perspectives were not significantly different from the control group (p>0.05) after six weeks of treatment. 
Other symptoms such as pain, insomnia and arm symptoms, were not significantly different.
Conclusion: AM is beneficial for improving emotional functioning and fatigue, as well as reducing symptoms of anxiety and 
depression among breast cancer patients after six one-hour sessions of weekly  treatment.
Keywords: Anxiety; Aromatherapy Massage; Breast Cancer; 
Depression; Fatigue; Quality of Life.
Introduction
Cancer patients in particular have sought out complementary 
therapies. Horneber et al. [1] reviewed studies of cancer patients 
using complementary therapies and concluded that usage had 
risen from 32% in the 1990’s to 49% after 2000. Corner et al. [2] 
compared massage and aromatherapy treatments with 52 patients 
receiving eight weekly treatments, those receiving AM had a 
greater improvement in symptom control.
A number of cancer support centres have incorporated 
complementary therapies into treatment regimens for cancer 
patients. At one centre, 58 patients (mainly female) and 40 per cent 
with a main symptom of anxiety, completed HADS questionnaires 
following six AM treatments, Kite [3] concluded that AM has a 
role in reducing psychological distress and improving symptom 
control in cancer patients. Harrington et al. [4] reported a service 
evaluation of users at three cancer support centres with breast 
cancer.  Patients received therapies to help relieve cancer treatment 
side effects and completed the Measure Yourself Concerns and 
Wellbeing (MYCaW) questionnaire before and after six one-hour 
complementary therapies. Listing et al. [5] concluded massage 
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improved mood and reduced physical discomfort and fatigue.
Wilkinson et al. [6] found that AM reduced psychological 
distress in the short term for cancer patients two weeks after 
intervention, and Imanishi et al. [7] reported this effect was 
measurable at four weeks. This finding is supported in reviews 
from Flemming [8] and Fellowes et al. [9]. 
Baum et al. [10] published a literature review which concluded 
that complementary and alternative medicine including AM is 
effective in decreasing anxiety levels and increasing quality of life. 
Wilkinson et al. [11] reviewed the evidence of the effectiveness of 
massage and AM for cancer patients in the reduction of physical 
and psychological symptoms. They concluded that AM may 
reduce anxiety in the short term and may improve the symptoms 
of pain and nausea.  Both of these concluded that larger trials and 
longer follow up periods were required to confirm the efficacy 
and effectiveness of massage for cancer patients. Dunn et al. [12] 
showed significant improvements in anxiety and quality of life. 
Boehm, Bussing and Osterman [13] published a descriptive 
systematic review of AM as an adjuvant treatment to cancer care, 
and found short-term improvements in well-being, anxiety and 
depression but no long lasting effects.
The ‘FORCE’ cancer support centre, situated on the site 
of the Royal Devon and Exeter NHS Foundation Trust hospital, 
offers a range of complementary therapies to cancer patients 
and their carers. Since the service started in 1997 it has received 
very positive anecdotal feedback from patients who expressed 
improvement in physical and emotional wellbeing, following 
complementary therapy treatments, particularly the AM. As most 
previous studies were small and reviews called for larger, well 
conducted trials, a randomized controlled trial was undertaken, 
using validated questionnaires, to attempt to measure any benefits 
of AM treatment.
Although complementary therapy was available for all 
cancer types presenting at the centre, in a scoping exercise of three 
months’ registrations, it was found that 43 percent were breast 
cancer patients, by far the largest diagnostic group, and Boon 
et al. [4] reported that uptake of CAM is highest among breast 
cancer patients - up to 80 per cent. For ease of recruitment, we 
therefore decided to study breast cancer patients.  The aim of this 
research was to evaluate whether AM is beneficial physically and 
emotionally for breast cancer patients.  The objectives of the study 
were to conduct a randomized controlled trial of AM versus no 
additional treatment, recruiting breast cancer patients at various 
stages of treatment and to use validated outcome measures such 
as HADS Zigmond & Snaith, [15] and EORTC QLQ-C30 and 
EORTC QLQ-BR23 (EORTC Charitable Trust) [16] focusing on 
pain, insomnia, nausea/vomiting, and emotional well-being as well 
as the ability to cope and feelings of anxiety.
Methods
This was a parallel arm, randomized controlled trial with 
1:1 allocation to the two arms. Eligible participants were breast 
cancer patients undergoing clinical treatment or who had recently 
completed treatment and were therefore on follow-up appointments. 
Inclusion criteria were any patient being treated for breast cancer 
aged 18 or over. Exclusion criteria were psychotic patients and 
those who did not meet the contraindications of aromatherapy. The 
setting was the complementary treatment facility of the FORCE 
Cancer Charity based in Exeter, Devon, UK. 
Ethical Approval
Ethical approval was granted by the North and East Devon 
Local Research Ethics Committee.
Flow Diagram: Consort 2010. 
Recruitment, Consent and Randomization
Breast cancer patients (age range 18 to 86 years) were 
recruited by the researcher from those requesting information 
about the centre’s complementary therapy service, or who were 
attending the service for additional support. Patients contacting the 
researcher were given an information sheet and had opportunity to 
discuss the trial.  Those recruited completed a consent form.
A computer-generated randomization list was produced 
by the statistician and random allocation was completed by the 
researcher-using sequentially numbered, opaque envelopes and 
allocation was concealed from therapists until interventions were 
assigned. All patients in both groups were given a code number 
Citation: Clemo-Crosby AC, Day J, Stidston C, McGinley S, Powell RJ (2018) Aromatherapy Massage for Breast Cancer Patients: A Randomised Controlled Trial. J Nurs 
Womens Health: JNWH-144. DOI: 10.29011/2577-1450. 100044
3 Volume 2018; Issue 01
J Nurs Womens Health, an open access journal
ISSN: 2577-1450
for anonymity which reflected the numbered set of questionnaires 
and a prepaid envelope for returning the completed forms. All 
questionnaires once returned were kept in a locked filing cabinet 
in a secure building.
It was not possible to blind patients or therapists but the 
analyst was blinded to group allocation.
Intervention and Control Groups
The randomized controlled trial offered the treatment group 
six appointments of AM once a week. A small team of experienced 
aromatherapists carried out the treatments. Whenever possible 
each aromatherapist would see the same patient for the duration of 
their six AM appointments. The AM treatment was individualized: 
there was a selection of seven essential oils (lavender, lemongrass, 
neroli, grapefruit, bergamot, frankincense, sandalwood). The 
aromatherapist made an individualized blend 1% from these oils 
for each patient, but the most common combination was lavender 
and bergamot. The oils used and treatment given were recorded 
on the patient’s complementary therapy notes which were kept 
in a locked filing cabinet. Patients were asked about any known 
allergy or sensitivity to these oils and adverse reactions to them 
were noted. Patients in the control group were put on a six week 
waiting list for AM if they desired it.
Outcome Measures
All participants were asked to complete two questionnaires, 
the HADS and the EORTC QLQ-C30 with additional BR23 
questions specific to breast cancer. The trial group were staged at 
pre-treatment, after the third and sixth treatments.
The control group completed questionnaires at baseline, 
three and six week intervals before being offered complementary 
therapy. The primary outcome was pain as measured by the EORTC 
questionnaire and the secondary outcomes included anxiety, 
depression, emotional reactions, fatigue, insomnia, breast and arm 
symptoms, ability to cope, side effects and future perspectives. 
These were also measured using the EORTC questionnaires.
Sample Size
The sample size calculation was based on evaluation data 
that had been collected from 133 patients with a variety of cancer 
diagnoses, before treatment and after six weeks of complementary 
therapy treatment. 58 per cent of patients were experiencing pain 
before treatment which had reduced to 42 per cent at six weeks. 
Based on these results, to be 80 per cent certain of detecting a 
change in pain score of 16 percentage points at the five per cent 
significance level, 153 patients per group would be needed (306 in 
total). In the eventual trial, 135 treatments and 149 controls (284 in 
total) were recruited and these were all breast cancer patients.
Statistical Analysis
Split-Plot Analysis of Variance was used as the study 
design, which included a combination of between subjects and 
within-subjects comparisons. Two arms of the trial were being 
compared (Between Subjects) and also the three time points 
(Within Subjects). Raw data were transferred from the EORTC 
and HADS questionnaires into Excel spreadsheets manually. 
These were checked for errors and missing data from unanswered 
questions were highlighted. Where possible, missing data were 
replaced by imputed values according to the guidelines supplied 
by EORTC. Domain scores, which are scaled from 0 to 100, were 
calculated and transferred into new spreadsheets for analysis. Data 
analysis was completed using SPSS Inc. Release 2009. PASW 
Statistics for Windows, Version 18.0. Chicago: SPSS Inc. The 
analyst was blind to treatment allocation. Scores were tested for 
normality using Shapiro-Wilk tests and inspection of plots and 
histograms. The trial data were analyzed using SPANOVA, which 
also requires independence of data, homogeneity of variances, 
sphericity (equal variances of repeated measurements: Mauchly’s 
test) and homogeneity of inter-correlations (equal variance-
covariance matrices across between-subject’s effects: Box’s M 
test). If sphericity was violated, adjusted results (e.g., Greenhouse-
Geisser) were interpreted. Results were expressed as mean domain 
scores with 95% confidence intervals for precision.
All tests were conducted at the five per cent significance level. 
Baseline EORTC scores were compared with those from a normal 
population (EORTC 2002). Cohen’s d effect sizes, categorized 
as small (0.2), medium (0.5) or large (0.8), were calculated for 
each outcome measure and EORTC domain Cohen [17]. No 
radiotherapy or chemotherapy sub-group analyses were attempted 
as there was insufficient power and a risk of Type II errors.
Results
The mean age of patients in the intervention group was 55.4 
years (sd 10.89, range 34 to 86 years) and in the control group 55.62 
years (sd 10.12, range 25 to 80 years). The proportions having 
chemotherapy were: intervention 58 (42 per cent) and control 72 
(48 per cent). Those having radiotherapy were intervention 37 (27 
per cent) and control 36 (24 per cent). Among the baseline EORTC 
scores, only the emotional functioning score was similar to that 
provided by EORTC (2002). The trial population scored higher 
on physical functioning, fatigue and insomnia and lower on role 
functioning and pain (see Table 1). 
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Domain EORTC mean        Trial Baseline mean 95% confidence interval
Emotional functioning 67.3                       68.6 (64 to 73.1)
Physical functioning                       73.6                       80.4 (77.2 to 83.6)
Role functioning                              76.6                       68.7 (63.0 to 74.1)
Fatigue                                        31.4                       41 (36.3 to 45.8)
Pain                                                      29.1                       20.4 (16.0 to 24.8)
Insomnia                                            31.1                       39.7 (33.3 to 46.2)
Table 1: A comparison of EORTC population domain scores and baseline scores measured in this trial.
EORCT Pain Scores
There was no significant difference in pain scores overall (p=0.409) and no significant change in pain score in the AM group from 
baseline: 19.56 (95per cent CI 15.61 to 24.01); six weeks: 17.4 (95percent CI 13.08 to 21.72). Neither the breast or arm symptoms were 
significantly different in main effects throughout the six-week trial period (p=0.179 and p=0.483 respectively) (Table 2).
 Aromatherapy (n = 110) Control: Usual care (n=106) Comparisons over 6 weeks
Measures Initial 3 weeks 6 weeks Initial 3 weeks 6 weeks 
Within 
subjects F 
with 1, 210 df
P 
value
Between 
subjects 
F with 1, 
210 df
P value 
(effect 
size)
HADs 
anxiety
7.15 (6.35, 
7.94)
6.14 (5.36, 
6.91)
5.20 
(4.41, 
5.99)
7.20 
(6.39, 
8.01)
7.08 (6.29, 
7.87)
7.07 
(6.27, 
7.87)
2.381 0.124 3.183 0.076 (0.44)
HADs 
depression
3.93 (3.33, 
4.53)
3.80 (3.17, 
4.40)
3.50 
(2.9, 
4.1)
4.63 
(4.02, 
5.24)
5.00 (4.38, 
5.62)
5.14 
(4.53, 
5.75)
2.03 0.156 9.338 0.003 (0.50)
EORTC 
physical 
functioning
80.43 
(77.29, 
83.57)
81.90 
(78.64, 
85.16)
82.10 
(79.00, 
85.20)
80.41 
(77.2, 
83.63)
78.57 (75.24, 
81.91)
79.34 
(76.20, 
82.54)
2.05 0.154 0.951 0.330 (0.18)
EORTC 
Role 
functioning
68.23 
(62.77, 
73.68)
71.12 
(65.54, 
76.70)
74.55 
(69.09, 
80.02)
68.56 
(62.98, 
74.14)
64.72 (59.01, 
70.43)
68.72 
(62.90, 
74.10)
1.286 0.258 1.46 0.228 (0.21)
EORTC 
fatigue
38.73 
(34.13, 
43.34)
35.54 
(30.98, 
40.10)
32.6 
(28.16, 
37.03)
41.03 
(36.31, 
45.75)
41.06 (36.39, 
45.73)
40.68 
(36.13, 
45.22)
0.598 0.44 3.681 0.056 (0.34)
EORTC 
emotional 
functioning
68.58 
(64.04, 
73.11)
75.27 
(71.00, 
79.54)
79.57 
(75.71, 
83.43)
68.58 
(63.93, 
73.23)
69.50 (65.12, 
73.87)
69.23 
(65.27, 
73.19)
1.1 0.295 4.073 0.045 (0.51)
EORTC 
insomnia
40.43 
(34.18, 
46.68)
34.99 
(29.24, 
40.74)
32.47 
(26.84, 
38.11)
39.74 
(33.31, 
46.17)
36.44 (30.52, 
42.35)
40.07 
(34.28, 
45.87)
0.784 0.377 0.563 0.454 (0.26)
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EORTC pain
19.86 
(15.61, 
24.01)
17.77 
(13.45, 
22.09)
17.4 
(13.08, 
21.72)
20.41 
(16.03, 
24.81)
19.99 (15.52, 
24.45)
21.21 
(16.75, 
25.68)
1.238 0.267 0.684 0.409 (0.18)
BR-23 
future 
perspectives
46.20 
(39.99, 
52.41)
57.13 
(51.04, 
63.21)
56.75 
(51.38, 
62.12)
45.55 
(39.34, 
51.76)
50.14 (44.05, 
56.22)
51.83 
(46.46, 
57.20)
0.46 0.632 1.297 0.256 (0.18)
BR-23 
systemic 
side effects
20.57 
(16.66, 
24.49)
19.09 
(15.89, 
22.30)
16.70 
(13.27, 
20.14)
24.19 
(20.19, 
28.18) 
20.40 (17.13, 
23.66)
20.63 
(17.13, 
24.13)
0.117 0.733 1.82 0.179 (0.23)
BR-23 
breast 
symptoms
20.57 
(16.66, 
24.49)
19.09 
(15.89, 
22.30)
16.70 
(13.27, 
20.14)
24.19 
(20.19, 
28.18)
20.40 (17.13, 
23.66)
20.63 
(17.13, 
24.13)
0.117 0.733 1.82 0.179 (0.23)
BR-23 arm 
symptoms
17.69 
(13.863, 
21.52)
15.47 
(12.18, 
18.77)
15.79 
(12.39, 
19.20)
19.07 
(15.11, 
23.03) 
17.89 (14.48, 
21.30)
16.77 
(13.25, 
20.29)
0.116 0.734 0.493 0.483 (0.07)
Table 2: Individual outcome measures in intention to treat analysis of all randomised patients.
HADS Anxiety and Depression Scores (0 to 21)
Mean HADS Anxiety scores were similar at baseline (AM group 7.15; control: 7.2) but improved in the AM group to 5.2 (95 
per cent CI: 4.41 to 5.99) at six weeks while remaining relatively unchanged in the control group 7.07 (95 per cent CI: 6.27 to 7.87). 
This gave a significant time by group interaction (p<0.001) but no overall difference between subjects (p=0.076). The cutoff for HADS 
anxiety and depression caseness is 8/21 Bjelland et al. [18].  There were 45 (42 per cent) anxiety cases in the aromatherapy group at 
baseline and 43 (41 per cent) in the control group. This reduced to 29 (26 per cent) after 6 weeks’ treatment but increased in the control 
group to 46 (44 per cent).
Mean HADS depression scores were not significantly different at baseline: AM 3.93 (95 per cent CI 3.33 to 4.53); control: 4.63, 
(95 per cent CI: 4.02 to 5.24) but while control group depression scores continued to worsen over six weeks, those in the AM group 
improved (see Figure 1), giving AM 3.5 (95 per cent CI 2.9 to 4.1); control: 5.14 (95 per cent CI: 4.53 to 5.75) at that time and significant 
between subject’s effects (p=0.003). There were 15 (13 per cent) depression cases in the aromatherapy group at baseline and 23 (21 per 
cent) in the control group. This reduced to 12 (10.9 per cent) after treatment but increased in the control group to 30, (28 per cent).
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Figure 1: Effect of AM versus control for HADS depression score over a 
6 week period. Mean scores (+/- 95% CI).
EORTC Emotional Functioning Scale (0 To 100)
Emotional functional scales of EORTC-30 were the same at 
baseline but while control scores remained relatively unchanged 
over six weeks, mean AM scores improved from 68.58 to 79.57 
(see Figure 2). The difference between the two groups overall was 
significant (p=0.045):  AM 79.57 (95 per cent CI 75.71 to 83.43); 
control group 69.23, (95 per cent CI 65.27 to 73.19).  Neither 
physical nor role functioning were significantly different in main 
effects overall (p=0.330 and p=0.228 respectively). EORTC 
symptom scores (0 to 100).
Figure 2: Effect of AM versus control on EORTC emotional functioning 
score over a 6-week period. Mean scores (+/- 95% CI).
Mean EORTC symptom scores of fatigue improved from 
38.73 to 32.6 in six weeks in the AM group but remained relatively 
unchanged in the control group (41.03 at baseline and 40.68 at 
six weeks). However, this difference at six weeks did not reach 
significance (p=0.056): AM score 32.6, (95 per cent CI 28.16 to 
37.03); control group 40.68, (95 per cent CI 36.13 to 45.22).
While EORTC insomnia scores improved steadily in the AM 
group, they also began to drop in the control group but rose again 
at six weeks. This resulted in no overall significant difference 
between the groups (p=0.454): AM insomnia score at six weeks 
32.47, (95per cent CI 26.84 to 38.11); control group score 40. 07, 
(95per cent CI 34.28 to 45.87). 
EORTC Side Effects and Future Perspectives Scores
There were no significant differences in side effects or the 
patient’s future perspectives over the six-week trial period (p=0.179 
and p=0.256 respectively). No serious adverse events occurred 
during the trial and no adverse reactions to the aromatherapy 
massage were recorded.
Discussion
When this research was planned, much of the data available 
from other studies had been collected from palliative care patients. 
This trial included patients who were undergoing clinical treatment, 
or who had recently completed treatment and were therefore on 
follow-up appointments. Molinaro et al. [19] stated the scarcity of 
articles when researching.
Many of the previously published studies on the outcomes of 
AM and massage treatment of cancer patients have been criticized 
for their limited sample size and lack of randomization of controls. 
Ernst [20] and Boehm et al. [3] carried out literature reviews and 
highlighted such limitations, concluding that this subject warranted 
further investigation in order to provide more conclusive data. The 
current study addresses these two issues by using a large number 
of participants in a randomized controlled trial.
Jane et al. [21] in reviewing the literature showed that 
massage had positive effects on pain, anxiety and depression. 
They identified that future studies would benefit from an extended 
number of massages and larger sample sizes.  
The patients in the study were all women with breast 
cancer.  Most of the improvements in the AM group relative to the 
control group were in anxiety, depression, fatigue and emotional 
functioning.  Medium effect sizes were observed for HADS anxiety 
(0.44), HADS depression (0.5), EORTC emotional functioning 
(0.51) and EORTC fatigue (0.34). Whilst insomnia, physical 
and role functioning, breast symptoms, side effects and future 
perspectives were not significantly different from the control group 
and had small effect sizes (around 0.2). Other symptoms such as 
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pain and arm symptoms, were not significantly different.
A weakness of the study was that some data were not returned 
or not completed on some of the questionnaires. Also, many of 
the patients were still receiving chemotherapy/radiotherapy and 
therefore some did not feel well enough to attend sessions and 
some lived a considerable distance from the centre. 58 (20 per 
cent) participants dropped out by the end of six weeks mostly in 
the control group (42, 28 %). The sample size was based upon data 
from a group of patients who were not all breast cancer patients 
but had other cancers. It is possible that pain was more of an 
issue for this group, so that the study was powered on a variable 
(Pain) that was not the most relevant for breast cancer patients. 
Blocking would have helped to keep numbers in both arms of the 
study even at all times. With questionnaires there is always the 
possibility for response bias to occur but this is less likely with 
the validated, self-completed EORTC cancer questionnaires used 
in this study. Although there is an effect on emotional status, 
anxiety and depression in this study, it is difficult to say what was 
responsible for this effect: the essential oils, the AM, or having 
time to relax in a quiet environment with the undivided attention of 
an aromatherapist. Any one of these in isolation or in combination 
may be responsible.
Strengths of the study are that this was a large trial with 
adequate participant numbers recruited into each of the two arms, 
in agreement with the sample size calculation. Six treatments were 
received. The researcher recruited all patients to this trial with 
concealment of random allocation from the aromatherapists, thus 
minimizing any selection bias.  The same aromatherapist treated 
the patient throughout their treatments whenever possible which 
provided consistency in the application of the essential oils.  As 
the EORTC questionnaire does not fully cover all aspects of 
psychological symptoms, a second validated questionnaire, HADS 
was also used.
Cawley [22] reviewing the evidence for the benefits of 
massage in general, demonstrated it to be effective for a range of 
conditions.  Fourteen research studies were found, dating from 1982 
to 1996. The aims were focusing on improvements in relaxation, 
coping with symptoms/symptom distress, mood, pain, anxiety 
states, depression, stress, psychological wellbeing and quality of 
life. Only eight studies had a statistical analysis and all reported 
significant improvements in outcomes. Six of the studies involved 
cancer patients and all but one study was statistically analyzed 
and they reported significant improvements in outcome such as 
anxiety, symptom distress, heart rate, pain (Males) and quality 
of life. Three of the 14 studies reviewed included AM. Cooke 
and Ernst [23] published a systematic review of evidence for the 
effectiveness of AM. Of the 12 trials identified, the six trials of AM 
massage were concentrated upon; the remaining six studies were 
unique comparisons of different AM interventions. These studies 
suggested that AM massage had a mild, transient anxiolytic effect. 
However, they argued that the effects of AM were probably not 
strong enough for it to be considered for the treatment of anxiety. 
The hypothesis that it is effective for any other indication was not 
supported by the findings of rigorous clinical trials.
Conclusion
We conclude that the provision of AM is a useful adjunct 
to conventional treatment for patients with breast cancer. There 
were improvements in emotional functioning and a reduction in 
anxiety and depression which were sustained for at least ten weeks 
from the commencement of the weekly one-hour therapy sessions 
provided over a six-week period.
The implications of the results reported here for clinical 
practice are for AM to be offered alongside orthodox treatments 
and as a part of integrated supportive cancer care. Further research 
would benefit from expanding this to selecting patients from other 
cancer groups and the involvement of male patients. AM could be 
provided on the wards with the expectation of improving patients’ 
symptoms, emotional states and well-being.
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